1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Irritable Bowel Syndrome with Constipation Drugs Market
2.2. Global Irritable Bowel Syndrome with Constipation Drugs Market, By Drug Type, 2023 (US$ Million)
2.3. Global Irritable Bowel Syndrome with Constipation Drugs Market, By Prescription type, 2023 (US$ Million)
2.4. Global Irritable Bowel Syndrome with Constipation Drugs Market, By Geography, 2023 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2023

3. Irritable Bowel Syndrome with Constipation Drugs Market: Competitive Analysis
3.1. Market Positioning of Key Irritable Bowel Syndrome with Constipation Drugs Market Vendors
3.2. Strategies Adopted by Irritable Bowel Syndrome with Constipation Drugs Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2023 Versus 2032

4. Irritable Bowel Syndrome with Constipation Drugs Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Irritable Bowel Syndrome with Constipation Drugs Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Lubiprostone
5.3.2. Linaclotide
5.3.3. Stimulant Laxatives - Bisacodyl
5.3.4. Osmotic Laxatives
5.3.5. Lactulose
5.3.6. Polyethylene Glycol

6. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Market Segmentation
6.3.1. Prescribed
6.3.2. Over the Counter Type (OTC)


7. North America Irritable Bowel Syndrome with Constipation Drugs Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
7.3. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)
7.4.Irritable Bowel Syndrome with Constipation Drugs Market: By Region, 2022-2032, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
7.4.1.1.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
7.4.1.2.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
7.4.1.3.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)

8. UK and European Union Irritable Bowel Syndrome with Constipation Drugs Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
8.3. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)
8.4.Irritable Bowel Syndrome with Constipation Drugs Market: By Region, 2022-2032, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
8.4.1.1.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
8.4.1.2.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
8.4.1.3.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
8.4.1.4.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)
8.4.1.5. France
8.4.1.5.1. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
8.4.1.5.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
8.4.1.6.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)

9. Asia Pacific Irritable Bowel Syndrome with Constipation Drugs Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
9.3. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)
9.4.Irritable Bowel Syndrome with Constipation Drugs Market: By Region, 2022-2032, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
9.4.1.1.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
9.4.1.2.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)
9.4.1.3. India
9.4.1.3.1. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
9.4.1.3.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
9.4.1.4.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
9.4.1.5.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
9.4.1.6.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)

10. Latin America Irritable Bowel Syndrome with Constipation Drugs Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
10.3. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)
10.4.Irritable Bowel Syndrome with Constipation Drugs Market: By Region, 2022-2032, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
10.4.1.1.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
10.4.1.2.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
10.4.1.3.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)

11. Middle East and Africa Irritable Bowel Syndrome with Constipation Drugs Market, 2022-2032, USD (Million)
11.1. Market Overview
11.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
11.3. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)
11.4.Irritable Bowel Syndrome with Constipation Drugs Market: By Region, 2022-2032, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
11.4.1.1.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
11.4.1.2.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Irritable Bowel Syndrome with Constipation Drugs Market: By Drug Type, 2022-2032, USD (Million)
11.4.1.3.2. Irritable Bowel Syndrome with Constipation Drugs Market: By Prescription type, 2022-2032, USD (Million)

12. Company Profile
12.1. Abbott Laboratories, Inc.
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Ardelyx, Inc.
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Astellas Pharma Inc.
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. AstraZeneca Plc.
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. Bayer AG
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Fresenius Kabi AG
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Ironwood Pharmaceuticals, Inc.
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Sanofi S.A.
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. SK Biopharmaceuticals Co., Ltd.
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Sucampo AG
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. Synergy Pharmaceuticals, Inc.
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives
12.12. Synthetic Biologics, Inc.
12.12.1. Company Overview
12.12.2. Financial Performance
12.12.3. Product Portfolio
12.12.4. Strategic Initiatives